Maria Miller asked the Secretary of State for Health (28 November 2006: Column 557W) (1) whether donepezil, rivastigmine and galantamine will continue to be available for all patient groups with Alzheimer’s disease until the proposed judicial review is completed; (2) what plans there are to keep under review the cost effectiveness of prescribing donepezil, rivastigmine…
Membership Required
You must be a HM Subscriber to view this content.
Already have an account? Sign In
©2025 All rights reserved LaingBuisson 
